Figure 2: Metastatic burden and survival of mice treated with MN-anti-miR10b and low-dose doxorubicin.
From: Therapy targeted to the metastatic niche is effective in a model of stage IV breast cancer
(a) Representative bioluminescence images of metastatic burden showing evidence of complete regression of metastases in animals treated with MN-anti-miR10b and low-dose doxorubicin. The images shown are representative of the results observed in the majority of animals in each group. (b) Quantitative analysis of relative metastatic burden (photon flux over the whole body) from all treatment groups indicating complete regression of metastases in experimental animals treated with MN-anti-miR10b and low-dose doxorubicin. (Data represent average ± s.e.m.; Within-Subjects ANOVA: *p < 0.05; **p < 0.001; values were compared to MN-scr-miR and low-dose doxorubicin) (c) Mortality. Cancer survival was significantly higher in the animals treated with MN-anti-miR10b and low-dose doxorubicin, compared to control groups. (d) Macroscopic images post-necropsy (lungs are shown). The majority of the animals treated with MN-anti-miR10b and low-dose doxorubicin presented with no evidence of lung macrometastases at necropsy. Results represent a summary of three independent trials.
